PMID- 33928158
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20220422
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2021
DP  - 2021
TI  - Clinical Efficacy and Safety of Zoledronic Acid Combined with PVP/PKP in the 
      Treatment of Osteoporotic Vertebral Compression Fracture: A Systematic Review and 
      Meta-Analysis of Randomized Controlled Trials.
PG  - 6650358
LID - 10.1155/2021/6650358 [doi]
LID - 6650358
AB  - OBJECTIVE: We conducted this meta-analysis to provide better evidence of the 
      efficacy and safety of zoledronic acid (ZA) combined with percutaneous 
      vertebroplasty/kyphoplasty (PVP/PKP) on osteoporotic vertebral compression 
      fracture (OVCF) and proposed a protocol for its application in clinical practice. 
      METHODS: All randomized controlled trials (RCTs) of ZA combined with PVP or PKP 
      compared to individual PVP/PKP for the management of patients with OVCFs were 
      included in this study. Electronic database searches were conducted from database 
      inception to November 2020, including the Cochrane Library, PubMed, Web of 
      Science, and Embase. The pooled data were analyzed using RevMan 5.3 software. 
      RESULTS: Seven RCTs with 929 subjects were finally included. All included studies 
      reported visual analog scores (VAS), and no statistically significant differences 
      were identified at follow-ups of 3 d and 1 w (P > 0.05). In contrast, significant 
      differences were observed at the 1 mo, 3 mo, 6 mo, and 12 mo follow-ups (P < 
      0.05). Two trials reported the Cobb angle and vertebral body height (VBH), 
      including 182 subjects without significant differences at the 12 mo follow-up (P 
      > 0.05). In addition, significant differences in the bone mineral density (BMD), 
      beta-isomerized C-terminal telopeptide of type I collagen (beta-CTX), N-terminal 
      propeptide of type I collagen (PINP), and N-terminal molecular fragment (N-MID) 
      levels were observed between the two groups (P < 0.05). All trials reported side 
      effects. Significant differences in recurrent fractures, fever, flu-like 
      symptoms, and arthralgia or myalgia were identified (P < 0.05); however, no 
      significant difference in postoperative leakage was detected (P > 0.05). 
      CONCLUSION: Compared to PVP/PKP alone, an additional ZA injection had advantages 
      of long-term analgesic effects with improved bone metabolism indexes. Moreover, 
      combination therapy significantly prevented complications and drug reactions were 
      well tolerated. Overall, this systematic review revealed that ZA combined with 
      PVP/PKP was an effective, safe, and comprehensive therapy for patients with 
      OVCFs.
CI  - Copyright (c) 2021 Yan Sun et al.
FAU - Sun, Yan
AU  - Sun Y
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
AD  - Department of Orthopaedics, China-Japan Friendship Hospital, Beijing 100029, 
      China.
FAU - Ma, Haoning
AU  - Ma H
AD  - Department of Orthopaedics, China-Japan Friendship Hospital, Beijing 100029, 
      China.
FAU - Yang, Feng
AU  - Yang F
AD  - Department of Orthopaedics, China-Japan Friendship Hospital, Beijing 100029, 
      China.
FAU - Tang, Xiangsheng
AU  - Tang X
AD  - Department of Orthopaedics, China-Japan Friendship Hospital, Beijing 100029, 
      China.
FAU - Yi, Ping
AU  - Yi P
AD  - Department of Orthopaedics, China-Japan Friendship Hospital, Beijing 100029, 
      China.
FAU - Tan, Mingsheng
AU  - Tan M
AUID- ORCID: 0000-0002-0511-9735
AD  - Department of Orthopaedics, China-Japan Friendship Hospital, Beijing 100029, 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210408
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 6XC1PAD3KF (Zoledronic Acid)
SB  - IM
MH  - Fractures, Compression/drug therapy/surgery/*therapy
MH  - Humans
MH  - *Kyphoplasty
MH  - Osteoporotic Fractures/drug therapy/surgery/*therapy
MH  - *Randomized Controlled Trials as Topic
MH  - Spinal Fractures/drug therapy/surgery/*therapy
MH  - Treatment Outcome
MH  - *Vertebroplasty
MH  - Zoledronic Acid/*adverse effects/*therapeutic use
PMC - PMC8049795
COIS- The authors have no competing interests to declare.
EDAT- 2021/05/01 06:00
MHDA- 2021/05/26 06:00
PMCR- 2021/04/08
CRDT- 2021/04/30 06:56
PHST- 2020/11/25 00:00 [received]
PHST- 2021/03/18 00:00 [revised]
PHST- 2021/03/25 00:00 [accepted]
PHST- 2021/04/30 06:56 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
PHST- 2021/04/08 00:00 [pmc-release]
AID - 10.1155/2021/6650358 [doi]
PST - epublish
SO  - Biomed Res Int. 2021 Apr 8;2021:6650358. doi: 10.1155/2021/6650358. eCollection 
      2021.